Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06398054

A Study to Investigate the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy

Comparison of the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy: a Randomized, Phase iv, Double-blind Trial

Status
Not Yet Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
190 (estimated)
Sponsor
ASST Fatebenefratelli Sacco · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

For outpatient hysteroscopy (OH), it is recommended to take a standard dose of NSAIDs or more hyoscine-n butyl bromide (HBB) an hour prior to the procedure to minimize pain during the first postoperative hour. As there is currently no clear consensus in the literature regarding the best approach to pain management associated with office hysteroscopy procedures. This Phase 4 study is being conducted to evaluate the effectiveness of oral ibuprofen alone and in combination with HBB to determine the most appropriate strategy for improving pain perception in outpatients.

Detailed description

This is a randomized, phase IV, double-blind, placebo-controlled clinical trial. The subjects will be randomly assigned into one of two treatment arms: * Group A (Ibuprofen ): will receive one tablet of ibuprofen 400 mg and two tablets of placebo (similar in size, structure and colour to HBB) * Group B (Ibuprofen plus HHB): will assume one tablet of ibuprofen 400 mg plus two tablets of HHB 10 mg. The purpose of this study is to evaluate the effectiveness of oral ibuprofen alone and in combination with HBB to determine the most appropriate strategy for improving pain perception in outpatients.

Conditions

Interventions

TypeNameDescription
DRUGIbuprofen 400 mgIbuprofen 400 mg tablet
DRUGHyoscine N-Butil BromideHyoscine N-Butil Bromide 10 mg two tablets
DRUGplaceboTwo tablets

Timeline

Start date
2024-10-01
Primary completion
2026-10-01
Completion
2026-10-01
First posted
2024-05-03
Last updated
2024-05-10

Source: ClinicalTrials.gov record NCT06398054. Inclusion in this directory is not an endorsement.